Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Insulin Resistance & Diabetes

Top single nucleotide polymorphisms affecting carbohydrate metabolism in metabolic syndrome: From the LIPGENE study

J. Delgado-Lista; P. Perez-Martinez; S. Juan; A. Garcia-Rios; A. I. Perez-Caballero; J. A. Lovegrove; C. A. Drevon; C. Defoort; E. E. Blaak; A. Dembinska-Kieć; U. Riśrus; E. Herruzo-Gomez; A. Camargo; J. M. Ordovas; H. Roche; J. Lopez-Miranda Top single nucleotide polymorphisms affecting carbohydrate metabolism in metabolic syndrome: From the LIPGENE study Journal of Clinical Endocrinology and Metabolism
Genetics Insulin Resistance & Diabetes Metabolic Syndrome

Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation

L. A. Powell; P. Crowe; C. Kankara; J. McPeake; D. R. McCance; I. S. Young; E. R. Trimble; A. McGinty Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation Clinical science
Insulin Resistance & Diabetes

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

W. D. Porter; P. R. Flatt; C. Hölscher; V. A. Gault Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice International Journal of Obesity
Insulin Resistance & Diabetes

Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

V. Pathak; P. R. Flatt; N. Irwin Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes Peptides
Insulin Resistance & Diabetes

Liraglutide: another reason to target prediabetes?

C. F. Murphy; N. G. Docherty; C. W. le Roux Liraglutide: another reason to target prediabetes? Oncotarget
Insulin Resistance & Diabetes

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial

D. Papamargaritis; W. Al-Najim; J. Lim; J. Crane; M. Lean; C. le Roux; B. McGowan; D. O'Shea; D. Webb; J. Wilding; M. J. Davies Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial BMJ Open
Insulin Resistance & Diabetes

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

R. J. McCrimmon; A. M. Catarig; J. P. Frias; N. L. Lausvig; C. W. le Roux; D. Thielke; I. Lingvay Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia
Insulin Resistance & Diabetes

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial

A. D. Miras; B. Pérez-Pevida; M. Aldhwayan; A. Kamocka; E. R. McGlone; W. Al-Najim; H. Chahal; R. L. Batterham; B. McGowan; O. Khan; V. Greener; A. R. Ahmed; A. Petrie; S. Scholtz; S. R. Bloom; T. M. Tan Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol
Insulin Resistance & Diabetes

Regulating the effects of GPR21, a novel target for type 2 diabetes

S. Leonard; G. K. Kinsella; E. Benetti; J. B. Findlay Regulating the effects of GPR21, a novel target for type 2 diabetes Scientific reports
Insulin Resistance & Diabetes

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

I. Lingvay; A. M. Catarig; J. P. Frias; H. Kumar; N. L. Lausvig; C. W. le Roux; D. Thielke; A. Viljoen; R. J. McCrimmon Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial The Lancet Diabetes and Endocrinology
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 … Page15 Page16 Page17 … Page34 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2025 ASOI